<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02388828</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 33514, 821715</org_study_id>
    <secondary_id>821715</secondary_id>
    <nct_id>NCT02388828</nct_id>
  </id_info>
  <brief_title>CART-meso Long-term Follow-up</brief_title>
  <official_title>Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-meso Gene Therapy Products in Cancer Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-therapeutic, long-term follow-up (LTFU) study of subjects who have received
      retroviral-based gene therapy products in cancer studies. All subjects in this LTFU protocol
      have received lentiviral modified T cells engineered to express an anti-mesothelin scFv
      Chimeric Antigen Receptor (CAR). This gene therapy product is called CART-meso. Lentiviruses
      are a subfamily of retroviruses. This protocol is designed in adherence with the November
      2006 Food and Drug Administration (FDA) Guidance for Industry, &quot;Monitoring for Delayed
      Adverse Events&quot; and &quot;Supplemental Guidance on Testing for Replication Competent Retrovirus in
      Retroviral Vector Based Gene Therapy Products and During Follow-up of Patients in Clinical
      Trials Using Retroviral Vectors &quot; and involves up to 15 years of monitoring of subjects who
      have been exposed to retrovirus-mediated gene transfer. Subjects will undergo biannual visits
      for a blood test evaluating persistence of cells with retroviral vector sequences, chemistry,
      hematology and tumor markers (as applicable). On annual visits, subjects will further undergo
      a physical exam and medical history (including concomitant medications and adverse events)
      with careful attention to features possibly related to retrovirus-induced diseases
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>within 24 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Subjects Who Have Received Lentiviral-based CART-meso Therapy</condition>
  <arm_group>
    <arm_group_label>Subjects who have received lentiviral-based CARTmeso therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lentiviral-based CART meso therapy</intervention_name>
    <arm_group_label>Subjects who have received lentiviral-based CARTmeso therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have received lentiviral-based CARTmeso therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be enrolled into this destination protocol because they have received
             CART-meso cells that were genetically modified with a lentiviral vector. All subjects
             who have participated in a lentiviral vector study under IND #15882 and have received
             CART-meso cells will be asked to participate in this protocol.

          -  Subjects 18 years of age and older

          -  Subjects who have provided informed consent prior to their study participation.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Haas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

